SearchProgram details
Brachytherapy [Kansai Medical University General Medical Center]
No.
Department of Radiology
Kansai Medical University Medical Center（Kinki/Osaka）
Advancement of high-precision high-dose-rate interstitial brachytherapy
Not only curative treatment but also palliative care
We have been advancing the precision of high-dose-rate (HDR) interstitial brachytherapy. We use the third-generation remote afterloading system, MicroSelectron-HDR. In addition to curative treatment, we are also engaged in palliative therapy.
- Genres
-
- Department
- Disease
- Examination Items/Treatments/Surgical method
- Region/Organ
- Program Summary
- Brachytherapy for Cancer
Target diseases: Gynecological cancers, prostate cancer, head and neck cancers, breast cancer, bone and soft tissue tumors, rectal and anal cancer, and others.
Curative, life-prolonging, and palliative effects can be expected by treating the tumor lesion.
The lesion must be in a site where a therapeutic applicator can be inserted and placed.
Necessary procedures such as anesthesia and analgesia/sedation must be feasible.
The lesion site should be able to maintain a certain degree of stability during treatment.
The patient must have received a cancer diagnosis and personally consent to brachytherapy.
Note: Eligibility for brachytherapy requires discussion not only with the attending physician but also with collaborating specialists for each disease. As a result, there may be cases where treatment is not indicated.
- Medical Institutions
-
Kansai Medical University Medical Center
〒570-8507
10-15 Fumizono-cho, City of Moriguchi,
Google Map Map
- Examination Items
- Setup Date
- Excluded days
- Eligibility Criteria/Exclusions for Treatment
- Age
Sex
Medical history of cancer treatment (summary of treatment course, surgery, chemotherapy, radiotherapy, etc.)
Comorbidities
Recent blood test results (including tumor markers with follow-up data from before treatment)
Imaging examinations
- Precautions / Contraindications
- Please note that treatment may not be possible in cases of uncontrolled HIV or other infectious diseases, or if patients have severe arrhythmia or cerebral infarction and cannot discontinue anticoagulant medication. Please confirm in advance.
